A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
Clinical trial NCT03999749 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03999749
- Sponsor
- NYU Langone Health
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-06-11
- Primary completion
- 2023-07-01
- Enrollment
- 71
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.